Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)

NCT03449173 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Type B3 Thymoma
Thymic Carcinoma

Interventions

DRUG: Sunitinib

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano